| Rus |  |
Eng |  |
The 15th Annual Meeting of Yalta European Strategy (YES) – “The Next Generation of Everything” – was held on September 13-15, 2018 in Kyiv. Over 600 leading politicians, diplomats, businessmen, civil activists and experts from 28 countries took part in the conference organized by the international forum YES.
The discussions was focused on the future – on the groundbreaking changes that will have a profound impact on all aspects of life like never before. Which innovations will disrupt society, economy and politics? What major global challenges are ahead? What is the future of the United States, the EU, NATO, the Russian Federation? How to protect democracy against manipulation by outside powers and resist disinformation?
An important focus will be the implications of disruptive innovation for Ukraine; and on the other hand the specific challenges Ukraine is facing in its transformation process and with the upcoming presidential and parliamentary elections.
Speakers of the forum included world-leading decision-makers, futurologists, historians, politicians, investors, security and media experts.
Yalta European Strategy (YES) introduced nightcap events for the participants of the 15th YES Annual Meeting to wind down at the end of the first conference day and discuss interesting topics in an informal atmosphere. YES invited leading politicians, opinion makers and business leaders to present their views on modern trends that define the world and Ukraine. The nightcaps were organized in partnership with the U.S. Embassy in Ukraine and America House, International Renaissance Foundation, Ukrainian-Jewish Encounter and the Atlantic Council, Mejlis of the Crimean Tatar people and Ministry of Information Policy of Ukraine, Western NIS Enterprise Fund and Embassy of the Republic of Estonia.
YES Nightcap "Technology in a fast changing world. Ukraine’s contribution to the growth of the world tech ecosystem"
Host: Western NIS Enterprise Fund
Speakers: professor Yury Gogotsi, Nano-technology scientist; Lenna Koszarny, CEO of Horizon Capital ; Yaroslav Azhniuk, CEO of Petcube; Pavel Vrzhesch, Co-Founder of Banda Agency; Sergei Leschenko, Member of the Parliament of Ukraine
Moderator: Charles Whitehead, Director of the Law, Technology and Entrepreneurship program at Cornell Tech; Professor of Law, Cornell University
How best to expand Ukraine’s growing innovative tech industry to the next level? What should be Ukraine’s future contributions to expanding the world’s tech ecosystem? This nightcap brought together some of the most prominent entrepreneurial thought leaders who are building and investing in successful world class companies in Ukraine. Participants got firsthand accounts from CEOs and top executives of such companies as Horizon Capital, Petcube, Banda Agency, professor Yury Gogotsi and Sergei Leschenko.
Thanks for the pictures to photographer Volodymyr Cheppel
Read more about YES on https://yes-ukraine.org
MXenes potential applications include sensors, wound healing materials, and drug delivery systems. A recent study explored how different synthesis methods affect the safety and performance of MXenes. By comparing etching conditions and intercalation strategies, researchers discovered that fine-tuning the surface chemistry of MXenes plays a crucial role in improving biocompatibility. These results provide practical guidelines for developing safer MXenes and bring the field one step closer to real biomedical applications.
Exellent news, our joint patent application with Drexel University on highly porous MAX phase precursor for MXene synthesis published. Congratulations and thanks to all team involved!
Last Call! Have you submitted your abstract for IEEE NAP-2025 yet? Join us at the International Symposium on "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene-focused conference in Europe this year! Final Submission Deadline: May 15, 2025. Don’t miss this exclusive opportunity to showcase your research and engage with world leaders in the MXene field!
We are excited to announce the publication of latest review article on MXenes in Healthcare. This comprehensive review explores the groundbreaking role of MXenes—an emerging class of 2D materials—in revolutionizing the fields of medical diagnostics and therapeutics. Read the full article here: https://doi.org/10.1039/D4NR04853A.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Congratulations to all collaborators with this interesting joint work!
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.
